Indaptus Therapeutics, Inc. announced the successful advancement of its Phase I trial investigating Decoy20 and plans to progress it into combination studies with a checkpoint inhibitor.
AI Assistant
INDAPTUS THERAPEUTICS INC
2024
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.